Teva Pharmaceutical Industries Limited

Svc Pharma LP

Purdue Pharma L.p.

Euro-celtique S.a.

Opko Pharmaceuticals, LLC

Finetech Pharmaceutical Ltd

Igor Rukhman

Gennady Nisnevich

Boris Pertsikov

Ben-Zion Dolitzky

Julia Kaftanov

Arie L Gutman

Boris Tishin

Irina Fedotev

Marina Etinger

Ram Khanolkar

Lev Yudovich

Evgeni Flyaks

Judith Aronhime

Shlomit Wizel

Robert J Kupper

Tamas Koltai

Tahir Ahmed

Zvi Harel

Ben Zion Dolitzky

Alexander Vilensky

Olga Grossman

Arie Gutman

Gennady A Nisnevich

Gennady A Nisnevish

Boris M Pertsikov

Marina M Etinger

Irina M Fedotev

Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The heptasulfated disaccharides administered orally have comparable bioavailability to the intravenous administered dosage form.

Pure heptasulfated disaccharides having improved oral bioavailability

Methods for making trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition is prepared by allowing a composition comprising (&#xb1;)-&#x394;-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol based on the total amount of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

[object Object]

Methods for making trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI and trans-(+)-&#x394;-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI composition is prepared by allowing a composition comprising (&#xb1;)-&#x394;-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI composition comprising at least about 99% by weight of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol based on the total amount of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(&#x2212;)-&#x394;-tetrahydrocannabinoI having a purity of at least about 98% based on the total weight of cannabinoids.

Methods for making trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition is prepared by allowing a composition comprising (&#xb1;)-&#x394;)-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol based on the total amount of trans-(&#x2212;)-&#x394;-tetrahydrocannabinol and trans-(+)-&#x394;-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(&#x2212;)-&#x394;-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

The invention provides a novel polymorphic form I of crystalline bimatoprost, method for preparation thereof and new crystalline intermediates in the preparation. This form I of crystalline bimatoprost is used in purification of crude bimatoprost and in storage of bimatoprost as active pharmaceutical intermediate. Use of the physical form of bimatoprost in the manufacture of a medicament is also disclosed.

Bimatoprost crystalline form I

Provided are a method of making irbesartan via a Suzuki coupling reaction and a novel intermediate, 2-butyl-3-(4'-bromobenzyl)-1,3-diazaspiro[4.4]non-1-ene-4-one, for such process. The novel process includes the step of reacting such intermediate with a protected imidazolephenylboronic acid.

Synthesis of irbesartan

Provided is a process for preparing valsartan and precursors thereof.

Process for the preparation of valsartan

This invention relates to novel amorphous losartan potassium, novel losartan potassium in a crystalline form that is a hydrate, novel crystalline losartan potassium Form IV and solvates thereof, novel crystalline losartan potassium Form V and solvates thereof, to processes for their preparation, to compositions containing them and to their use in medicine. This invention further relates to a novel process for preparing crystalline losartan potassium Form I and Form II.

Amorphous and crystalline forms of losartan potassium and process for their preparation

Provided is a novel method of making 2-butyl-3-[[2'(1-trityl-1H-tetrazol-5-yl)biphen-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-ene-4-one, which can be converted to irbesartan. Also provided are methods of making irbesartan.

Synthesis of 2-butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one

Intermediates for the synthesis of irbesartan

Provided are process for the preparation of valsartan and the precursors thereof.

Process for the preparation of valsartan and intermediates thereof

Growing community of inventors

Haifa, Israel

Igor Rukhman